- WKN: A2LQ90
- ISIN: DE000A2LQ900
- Land: Deutschland
Nachricht vom 15.05.2018 | 07:05
MOLOGEN AG: significant progress in clinical studies and successful funding and licensing activities dominated first quarter of 2018
DGAP-News: MOLOGEN AG / Key word(s): Quarterly / Interim Statement/Quarter Results
Press Release N 13 / 2018 dated 05/15/2018
- Next Level corporate strategy being implemented according to plan
- Progress made in ongoing clinical trials and preparations underway for new studies in various indications
- A licensing and development cooperation contract signed with ONCOLOGIE; first payment received
- Additional capital measures successfully completed
- Confirmation of forecast for fiscal year 2018
Further successes were achieved in partnering activities and the associated commercialization of lefitolimod: a licensing and development contract was concluded with ONCOLOGIE, a U.S. drug development company, with MOLOGEN receiving the first contractual payment of EUR3 million. The ongoing financing requirements of the Company were also an important focus over the first quarter of 2018: financing has presumably been secured until the end of 2018 through the implementation of various capital measures.
Significant progress in current clinical studies and planning of new trials
The pivotal IMPALA study in the indication of colorectal cancer again moved forward as planned. In April 2018, an initial data-based forecast was published for the expected date for the primary analysis of the study. Based on patient data collected and using adequate statistical methodology, the results on the primary endpoint of the study are expected to be available in April 2020. This statistical forecast involves a degree of uncertainty, reflected in the 95% confidence interval of plus/minus five months. This translates into a time window from year-end 2019 to summer 2020 in which the time point for the analysis will fall with a high probability.
In 2018, MOLOGEN is starting a further clinical trial in the indication HIV together with Aarhus University Hospital and other prominent international centers, which is being funded by the U.S. biopharmaceutical company, Gilead Sciences Inc. In this trial, lefitolimod will be tested in combination with innovative virus-neutralizing antibodies. Preparatory work for the start of this follow-up study, which is entitled TITAN is currently underway. Other new studies in the area of immuno-oncology are also in the pipeline.
First licensing and development cooperation with lead compound lefitolimod
Additional capital measures successfully completed
Also in February, MOLOGEN entered into an agreement with the Luxembourg financing provider European High Growth Opportunities Securitization Fund (EHGO), a fund advised by Alpha Blue Ocean Advisors (ABO). Pursuant to this agreement, MOLOGEN can place convertible bonds in an aggregate amount of up to EUR12 million in up to 24 tranches of EUR500,000 each with the investor over a period of two years. So far, MOLOGEN has obtained two tranches in March 2018 and generated gross proceeds of EUR1 million as a result.
In March, MOLOGEN also successfully concluded a further capital increase from authorized capital. In the course of the capital increase that was fully placed with national and international investors, MOLOGEN received gross proceeds amounting to approximately EUR5 million.
Research and development expenses
On the personnel side, MOLOGEN AG announced shortly after the end of the reporting period that for personal reasons, CEO Dr Mariola Soehngen will not extend her contract after the expiry date 31 October 2018. The Executive Board and Supervisory Board accepted this decision with great regret.
The complete MOLOGEN AG report for the first quarter of 2018 is available on the website: www.mologen.com.
The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in small cell lung cancer have been announced in April 2017, and the final analysis in the first quarter 2018 confirmed the data. Furthermore, data from the extension phase of the TEACH study in HIV have also been published in 2017. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN DE0006637200, SIN 663720) are listed in the Prime Standard of the German Stock Exchange.
Note about risk for future predictions
|Phone:||030 / 841788-0|
|Fax:||030 / 841788-50|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|
UniDevice AG: Rekord-Ergebnis in 2018
Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.
Der AKTIONÄR News
21. Februar 13:10 Commerzbank: Das müssen Anleger zur Dividende wissen
21. Februar 11:57 Trendwende bei Shortsellern: Der Fall Aixtron
21. Februar 11:02 Bestimmen diese Zahlen die Zukunft von Gold und Minen?
21. Februar 11:00 SAP Vorstand geht – Fokus bleibt auf Umstrukturierung
21. Februar 10:33 Munich Re: Strategiewechsel bringt Kursgewinne
News im Fokus
Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2018
21. Februar 2019, 11:51
Vorläufige Geschäftszahlen 2018
26. Februar 2019
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
20. Februar 2019